理气药治疗肝纤维化作用的研究进展  

Research Progress of Regulating-Qi Drugs in the Treatment of Liver Fibrosis

作　　者：蒋云霞[1] 罗伟生[1] JIANG Yunxia;LUO Weisheng(Guangxi University of Chinese Medicine,Nanning 530000,China)

机构地区：[1]广西中医药大学,广西南宁530000

出　　处：《西部中医药》2023年第4期133-136,共4页Western Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金(81660779);广西创新驱动发展专项公开择优立项项目(基金号:2017AA21041);2018年广西一流学科建设项目重点课题(2018XK035)。

摘　　要：对理气类中药,如香附、荔枝核、小茴香及化瘀理气类中药,如郁金、姜黄、莪术治疗肝纤维化的作用机制及相关研究进行梳理。认为在药物的抗肝纤维化作用机制研究方面,仍缺乏完整、准确的对分子机制及其信号传导通路的研究。在之后的研究与实验过程中,应立足于中医理论与古籍论述,发展现代的药剂药理学实验与临床研究,更为深入地探讨各味中药是否具有治疗肝纤维化的作用及其相关机制,并将其合理运用到之后的中药研制与开发当中。The paper reviews the mechanism and the relevant study on regulating-Qi herbs including Xiangfu(Cyperi rhizoma),Lizhihe(Litchi semen),Xiaohuixiang(Foeniculi fructus),and stagnation-resolving Qiregulating herbs such as Yujin(Curcumae Radix),Jianghuang(Curcumae longae rhizoma),Ezhu(Curcumae rhizoma)in the treatment of liver fibrosis.The research on the mechanism of anti-liver fibrosis action of drugs lacks the complete and accurate studies on molecular mechanism and its signaling pathways.In the subsequent research and experimental process,modern pharmacological pharmacology experiments and clinical research should be developed based on the theory of traditional Chinese medicine and ancient books,in order to further discuss whether different herbs owns therapeutic effects for liver fibrosis and the relevant mechanism,and it will be rationally applied to the later development of herbs.

关 键 词：肝纤维化 理气 中医中药 研究进展 

分 类 号：R256.43[医药卫生—中医内科学]